IVeena Delivery Systems announced positive results from a pilot trial for its bioerodible implant for treatment of pain and inflammation after cataract surgery.
The implant, IVMED-10, is placed during cataract surgery and releases dexamethasone for 2 weeks. In the trial, eight patients were implanted with IVMED-10. The device was found to be safe and effective for control of inflammation, and retinal thickness outcomes were comparable to NSAID and steroid standard of care therapy, according to a press release from iVeena.
Adverse events included elevated IOP, corneal edema and pain, but all
Uncategorized